Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: A randomized controlled trial

JAMA

Volumn 300, Issue 5, 2008, Pages 509-519

  Lo, Janet ^a   You, Sung Min ^a   Canavan, Bridget ^a   Liebau, James ^a   Beltrani, Greg ^a   Koutkia, Polyxeni ^a   Hemphill, Linda ^a   Lee, Hang ^a   Grinspoon, Steven ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GROWTH HORMONE RELEASING FACTOR; HUMAN GROWTH HORMONE; PLACEBO; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; ARTHRALGIA; ARTICLE; BIOCHEMISTRY; BLOOD PRESSURE; BODY COMPOSITION; CARDIOVASCULAR FUNCTION; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HORMONE RELEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERGLYCEMIA; HYPERTENSION; IMMUNE FUNCTION TEST; INTRAABDOMINAL FAT; LIPID STORAGE; MALE; ORAL GLUCOSE TOLERANCE TEST; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; SIDE EFFECT; SKIN TINGLING; SOMATOMEDIN C BLOOD LEVEL; SWELLING; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 48749093932     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.5.509     Document Type: Article

References (45)

1. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349(21):1993-2003.
2. Rietschel P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metab. 2001;86(2):504-510.
3. Koutkia P, Canavan B, Breu J, Grinspoon S. Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy. J Clin Endocrinol Metab. 2005;90(1):32-38.
4. Koutkia P, Eaton K, You SM, Breu J, Grinspoon S. Growth hormone secretion among HIV infected patients: effects of gender, race and fat distribution. AIDS. 2006;20(6):855-862.
5. Rosén T, Bosaeus I, Tölli J, Lindstedt G, Bengtsson BA. Increased body fat mass and decreased extracellular fluid volume in adults with growth hormone deficiency. Clin Endocrinol (Oxf). 1993;38(1):63-71.
6. Salomon F, Cuneo RC, Hesp R, Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med. 1989;321(26):1797-1803.
7. Merimee TJ, Hollander W, Fineberg SE. Studies of hyperlipidemia in the HGH-deficient state. Metabolism. 1972;21(11):1053-1061.
8. De Boer H, Blok GJ, Voerman HJ, De Vries PM, van der Veen EA. Body composition in adult growth hormone-deficient men, assessed by anthropometry and bioimpedance analysis. J Clin Endocrinol Metab. 1992;75(3):833-837.
9. Rosén T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet. 1990;336(8710):285-288.
10. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993;76(2):309-317.
11. Friedman M, Byers SO, Rosenman RH, Li CH, Neuman R. Effect of subacute administration of human growth hormone on various serum lipid and hormone levels of hypercholesterolemic and normocholesterolemic subjects. Metabolism. 1974;23(10):905-912.
12. Blackett PR, Weech PK, McConathy WJ, Fesmire JD. Growth hormone in the regulation of hyperlipidemia. Metabolism. 1982;31(2):117-120.
13. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomized, controlled clinical trial. Ann Intern Med. 2000;133(2):111-122.
14. Johansson JO, Fowelin J, Landin K, Lager I, Bengtsson BA. Growth hormone-deficient adults are insulin-resistant. Metabolism. 1995;44(9):1126-1129.
15. Hew FL, Koschmann M, Christopher M, et al. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab. 1996;81(2):555-564.
16. Johannsson G, Marin P, Lonn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab. 1997;82(3):727-734.
17. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab. 2002;87(5):2121-2127.
18. Hwu CM, Kwok CF, Lai TY, et al. Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience. J Clin Endocrinol Metab. 1997;82(10):3285-3292.
19. Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35(3):239-252.
20. Grunfeld C, Thompson M, Brown SJ, et al. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr. 2007;45(3):286-297.
21. Lo JC, Mulligan K, Noor MA, et al. The effects of low-dose growth hormone in HIV-infected men with fat accumulation: a pilot study. Clin Infect Dis. 2004;39(5):732-735.
22. Hoffman DJ, Wang Z, Gallagher D, Heymsfield SB. Comparison of visceral adipose tissue mass in adult African Americans and whites. Obes Res. 2005;13(1):66-74.
23. Koutkia P, Canavan B, Breu J, Toriani M, Kissko J, Grinspoon S. Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized, controlled trial. JAMA. 2004;292(2):210-218.
24. Lo J, Dolan SE, Kanter JR, et al. Effects of obesity, body composition, and adiponectin on carotid intima-media thickness in healthy women. J Clin Endocrinol Metab. 2006;91(5):1677-1682.
25. Wu AW, Revicki DA, Jacobson D, Malitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res. 1997;6(6):481-493.
26. Delate T, Coons SJ. The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clin Infect Dis. 2001;32(3):E47-E52.
27. Djurhuus CB, Gravholt CH, Nielsen S, Pedersen SB, Moller N, Schmitz O. Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab. 2004;286(3):E488- E494.
28. Ottosson M, Vikman-Adolfsson K, Enerback S, Elander A, Bjorntorp P, Eden S. Growth hormone inhibits lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab. 1995;80(3):936-941.
29. Richelsen B, Pedersen SB, Borglum JD, Moller-Pedersen T, Jorgensen J, Jorgensen JO. Growth hormone treatment of obese women for 5 wk: effect on body composition and adipose tissue LPL activity. Am J Physiol. 1994;266(2 pt 1):E211-E216.
30. Schwarz JM, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2002;87(2):942.
31. Brandou F, Aloulou I, Razimbaud A, Fedou C, Mercier J, Brun JF. Lower ability to oxidize lipids in adult patients with growth hormone (GH) deficiency: reversal under GH treatment. Clin Endocrinol (Oxf). 2006;65(4):423-428.
32. Dolan SE, Frontera W, Librizzi J, et al. The effects of a supervised home-based aerobic and progressive resistance training regimen in HIV-infected women: a randomized trial. Arch Intern Med. 2006;166(11):1225-1231.
33. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA. 2000;284(4):472-477.
34. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized controlled trial. Ann Intern Med. 2004;140(10):786-794.
35. Lo JC, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2001;86(8):3480-3487.
36. Falutz J, Allas S, Kotler D, et al. A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation. AIDS. 2005;19(12):1279-1287.
37. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359- 2370.
38. Soares DV, Spina LD, de Lima Oliveira Brasil RR, et al. Carotid artery intima-media thickness and lipid profile in adults with growth hormone deficiency after long-term growth hormone replacement. Metabolism. 2005;54(3):321-329.
39. Colao A, Di Somma C, Rota F, et al. Short-term effects of growth hormone (GH) treatment or deprivation on cardiovascular risk parameters and intima-media thickness at carotid arteries in patients with severe GH deficiency. J Clin Endocrinol Metab. 2005;90(4):2056-2062.
40. Colao A, Di Somma C, Cuocolo A, et al. Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? results of a two-year open, prospective study in young adult men and women with severe GH deficiency. J Clin Endocrinol Metab. 2005;90(9):5146-5155.
41. Napolitano LA, Schmidt D, Gotway MB, et al. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest. 2008;118(3):1085-1098.
42. Carr DB, Utzschneider KM, Boyko EJ, et al. A reduced-fat diet and aerobic exercise in Japanese Americans with impaired glucose tolerance decreases intra-abdominal fat and improves insulin sensitivity but not beta-cell function. Diabetes. 2005;54(2):340-347.
43. Fujimoto WY, Jablonski KA, Bray GA, et al. Body size and shape changes and the risk of diabetes in the diabetes prevention program. Diabetes. 2007;56(6):1680-1685.
44. Park HS, Lee K. Greater beneficial effects of visceral fat reduction compared with subcutaneous fat reduction on parameters of the metabolic syndrome: a study of weight reduction programmes in subjects with visceral and subcutaneous obesity. Diabet Med. 2005;22(3):266-272.
45. Snyder S. Regulatory considerations for the treatment of lipodystrophy. In: Cheng B, Miller V, eds. Forum for Collaborative HIV Research Roundtable Discussion. Washington, DC: George Washington University School of Public Health and Health Services; 2004.